<ѻý>FDA Greenlights First Drug for ESR1-Mutated Breast Cancerѻý> Elacestrant almost doubled PFS versus standard endocrine therapy in advanced ER+/HER2- disease Jan 30, 2023
<ѻý>Immunotherapy Survival Gains 'Less Impressive' in Older Lung Cancer Patientsѻý> Study finds median OS improvement of just 1 month for patients 75 and older Jan 26, 2023
<ѻý>MDM2 Inhibitor Breaks Through in Trial of Liposarcoma, Other Advanced Malignanciesѻý> Intermittent dosing dramatically reduced myelosuppression that has hindered drug class Jan 26, 2023
<ѻý>New Class of Factor VIII Replacement Therapy Prevents Bleeds in Severe Hemophilia Aѻý> Weekly dosing with efanesoctocog alfa reduced annualized bleeding rate by 77% Jan 25, 2023
<ѻý>Inflammatory VEXAS Syndrome May Not Be So Uncommonѻý> Is new disease being missed by physicians? Jan 24, 2023
<ѻý>Neoadjuvant Chemo Reduces Disease Recurrence in Operable Colon Cancerѻý> Consider it now "an option" for locally advanced disease, editorialists say Jan 24, 2023
<ѻý>New Standard of Care for Refractory Metastatic Colorectal Cancerѻý> Significant improvement in OS, PFS with addition of bevacizumab to trifluridine/tipiracil Jan 23, 2023
<ѻý>What Caused a Man to Develop Friable Bleeding Nodules on His Arms and Hips?ѻý> The cause lies in a lengthy history of cancer treatment, confirmed by histopathology analysis Jan 23, 2023
<ѻý>'More Is Not Better' in Two First-Line Trials for Biliary Tract Cancerѻý> No survival benefit with three-drug chemo regimen or clear PFS gain with anti-PD-L1/bevacizumab Jan 22, 2023
<ѻý>New First-Line Standard for Metastatic Pancreatic Cancerѻý> Liposomal irinotecan regimen boosts outcomes, although expert expressed concern about toxicity Jan 22, 2023
<ѻý>Adding Targeted Drug to Chemo Boosts Survival in Gastric/GEJ Cancerѻý> Longest overall survival reported to date with the addition of zolbetuximab to chemotherapy Jan 21, 2023
<ѻý>We're Underutilizing Genetic Testing for Colorectal Cancerѻý> Universal germline testing should be part of the standard of cancer care Jan 20, 2023
<ѻý>Perioperative Chemo Matches Multimodal Tx for Locally Advanced Esophageal/GEJ Cancerѻý> Nearly identical 3-year survival, questioning the need for radiotherapy before surgery Jan 20, 2023
<ѻý>Circulating Tumor DNA Could Guide Use of Chemo in Colorectal Cancerѻý> Identified patients likely to benefit following surgery, large prospective study showed Jan 19, 2023
<ѻý>Short-Course Apalutamide to Reduce Active Surveillance Attrition in Prostate Cancerѻý> Editorialists question whether any intervention violates principles of surveillance Jan 17, 2023
<ѻý>Epstein-Barr Virus Tracking After Liver Transplant May Cut Rare Complicationѻý> Observational study provides suggestive evidence Jan 17, 2023
<ѻý>The Unfulfilled Promise of Cannabis for Cancer-Related Symptomsѻý> Medical cannabis is currently too far removed from the standards of medical practice Jan 14, 2023
<ѻý>For People With HIV, Early Anal Cancer Screening Tied to Better Outcomesѻý> All people with HIV should be screened, not just men who have sex with men, researchers say Jan 13, 2023
<ѻý>Off-the-Shelf T-Cell Therapy Effective Against Viral Infections After Allo-HCTѻý> Produced an antiviral response in 95% of patients with six different types of infection Jan 13, 2023
<ѻý>MRI-Guided Focused Ultrasound Eases Pain From Bone Metastasesѻý> More responses with ultrasound, but quality-of-life scores lower vs EBRT in nonrandomized trial Jan 11, 2023
<ѻý>Study Supports Routine Omentectomy in Absence of Metastasis During CRS-HIPECѻý> High rate of occult metastases in patients with grossly normal omentum Jan 11, 2023
<ѻý>Bariatric Surgery May Reduce Risk of Esophageal, Gastric Cancersѻý> Cohort study provides "reassurance of the protective clinical benefits of weight loss surgery" Jan 11, 2023
<ѻý>Zanubrutinib Shows Good Tolerance in BTK-Inhibitor Intolerant Malignanciesѻý> Most patients had no recurrence of their original intolerance event Jan 10, 2023
<ѻý>Post-HSCT Brentuximab Vedotin Plus Nivolumab Highly Effective in Hodgkin Lymphomaѻý> However, toxic effects might limit the combination to the highest-risk patients Jan 10, 2023
<ѻý>Conspiracy Theorists' Cancer Beliefs; HIV Meds and Ethnicityѻý> Also in TTHealthWatch: sodium levels and health outcomes Jan 07, 2023 podcast
<ѻý>Genomic Assay May Pinpoint Who Can Skip RT After Breast-Conserving Surgeryѻý> Patients categorized as low risk with 16-gene signature showed no significant benefit with RT Jan 06, 2023
<ѻý>More Evidence to Support Restrictive Opioid Prescribing After Cancer Surgeryѻý> Significant decreases in prescription days, doses, refill requests, with few patient complaints Jan 06, 2023
<ѻý>Optimizing Treatment for Older Patients With HR+ Low-Risk Breast Cancerѻý> Five days of radiotherapy, five years of hormonal therapy, or somewhere in between? Jan 05, 2023
<ѻý>More Extensive Resection of Low-Grade Glioma Linked to Longer Survivalѻý> Across both subtypes, improved survival seen with at least 75% resection, study finds Jan 05, 2023
<ѻý>Watch for New Psych Disorders in the Spouses of Cancer Patientsѻý> Risk especially high within the first year after cancer diagnosis Jan 05, 2023
<ѻý>Jazz Musician With Slowly Expanding Neck Mass Causing Dysphagiaѻý> Alcoholism, liver dysfunction highly linked with rare disease of unknown etiology Jan 04, 2023
<ѻý>Can Dying Well Be a Part of Living Well?ѻý> Shoshana Ungerleider, MD, on her mission to transform end-of-life care Jan 03, 2023 podcast
<ѻý>Crystal Ball Cloudy for PI3K Inhibitors' Future in Hematologyѻý> After a year of negative news, some caution about throwing out the baby with the bath water Jan 02, 2023
<ѻý>Adagrasib Shows Anti-Tumor Activity in Heavily Pretreated KRAS-Mutant CRCѻý> Response rates of 19% alone, 46% with cetuximab in phase I/II trial Dec 21, 2022
<ѻý>Early Win for Gene Therapy in Rare Form of SCIDѻý> 10 infants were able to make their own T cells; safety good so far Dec 21, 2022
<ѻý>Mixed Results With Hormonal Strategies for Premenopausal Breast Cancerѻý> Exemestane reduced recurrence, metastasis versus tamoxifen, but no survival benefit Dec 20, 2022
<ѻý>Long-Term Data Reinforce Targeted Combo Versus Single Agent for Advanced Melanomaѻý> Encorafenib-binimetinib tops vemurafenib, but checkpoint inhibitors remain first-line choice Dec 19, 2022
<ѻý>OS Benefit Eludes Second-Line Niraparib Maintenance in Ovarian Cancerѻý> Significant PFS results demonstrated in NORA trial don't extend to overall survival Dec 17, 2022
<ѻý>FDA Approves First Gene Therapy for Non-Muscle-Invasive Bladder Cancerѻý> Half of patients achieved complete responses with adenoviral vector-based product Dec 16, 2022
<ѻý>Anti-PD-1 Drugs Impress as Frontline Therapy for Early, Unfavorable Hodgkin'sѻý> 3-year PFS of 99%, OS of 100% with nivolumab-chemo, high response rate with pembrolizumab Dec 16, 2022